Selecta Biosciences to Present New Data for the ImmTOR™ platform at the ESGCT 28th Annual Congress

WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced it will be presenting preclinical data in four posters highlighting its ImmTOR nanoparticle platform and its potential to safely enable repeat vector dosing in gene therapy patients at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) taking place virtually from October 19-22, 2021.

Click here to view original post